Skip to main content

Find Clinical Trials

Home
Conditions
Pancreatic Cancer Resectable

Clinical trial condition

Pancreatic Cancer Resectable

Explore clinical trials studying Pancreatic Cancer Resectable. Study availability and eligibility vary by location and protocol.

31 public trials 11 recruiting studies

Refine in advanced search Browse all conditions

Pancreatic Cancer Resectable trial results

Recruiting

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

NCT06368063

Conditions: Pancreatic Cancer Resectable
Locations: Zheng Wang Xi'an, Shannxi, China

View Trial Details

Not Yet Recruiting

Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases

NCT07713823

Conditions: Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

NCT07698613

Conditions: Pancreatic Cancer Borderline, Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Resectable
Locations: Rhode Island and the Miriam Hospitals (Brown University Health) Providence, Rhode Island, United States

View Trial Details

Not Yet Recruiting

A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

NCT07592819

Conditions: Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable
Locations: Not specified

View Trial Details

Not Yet Recruiting

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT07488884

Conditions: Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +7 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

NCT07469956

Conditions: Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, China

View Trial Details

Not Yet Recruiting

Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer

NCT07155629

Conditions: Pancreatic Cancer Resectable
Locations: Helsinki University Central Hospital Helsinki, Finland

Oulu University Hospital Oulu, Finland

View Trial Details

Not Yet Recruiting

Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

NCT06941987

Conditions: Minimal Residual Disease, Neoplasm, Residual, Neoplasms, +4 more
Locations: Zhongshan Hospital, Shanghai Shanghai, China

View Trial Details

Not Yet Recruiting

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

NCT06888674

Conditions: Pancreatic Cancer Resectable
Locations: First Affiliated Hospital of Zhejiang University Schlool of Medicine Hangzhou, Zhejiang, China

View Trial Details

Not Yet Recruiting

Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer

NCT06868693

Conditions: Borderline Pancreatic Inoperable Cancer, Digestive System Diseases, Digestive System Neoplasms, +10 more
Locations: Not specified

View Trial Details